Business

Cholesterol Drug Setback for Pharmaceutical Giants

Updated 2026-09-08 05:10 UTC 1 source Negative

Novartis' failure to develop a cholesterol-lowering drug has cast doubt on Amgen and Eli Lilly's ongoing multibillion-dollar race. The setback could impact their strategies in the heart disease prevention market.

Coverage timeline — 1 article

CNBC

Cholesterol drug setback casts doubt over multibillion-dollar race

Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.

2026-09-08 05:00 UTC